Assimilating the Evidence in T2DM
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Meeting Slides
Clinical Practice Guidelines
Standards of medical care in diabetes—2020.
American Diabetes Association. Diabetes Care. 2020;43(suppl 1):S1-S212.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary.
Garber AJ, Handelsman Y, Grunberger G, et al. Endocr Pract. 2020;26(1):107‐139.
Patient and Caregiver Resources
American Association of Diabetes Educators
American Diabetes Association
Centers for Disease Control and Prevention: Diabetes Education and Support
National Diabetes Education Program
Suggested Readings
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Cannon CP, McGuire DK, Pratley R, et al. Am Heart J. 2018;206:11-23.
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
DeFronzo RA, Norton L, Abdul-Ghani M. Nat Rev Nephrol. 2017;13(1):11-26.
Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus.
Kato ET, Silverman MG, Mosenzon O, et al. Circulation. 2019;139(22):2528‐2536.
Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.
King RJ, Grant PJ. Herz. 2016;41(3):184-192.
Diabetes mellitus and heart failure.
Lehrke M, Marx N. Am J Cardiol. 2017; 120(suppl 1):S37-S47.
Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
Maack C, Lehrke M, Backs J, et al. Eur Heart J. 2018;39(48):4243‐4254.
Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.
Mahaffey KW, Jardine MJ, Bompoint S, et al. Circulation. 2019;140(9):739-750.
Dapagliflozin in patients with heart failure and reduced ejection fraction.
McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med. 2019;381(21):1995-2008.
Canagliflozin and cardiovascular and renal events in type 2 diabetes.
Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med.2017;377(7):644-657.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.
Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019;380(24):2295-2306.
Timing of onset of clinical benefit with dapagliflozin in patients with heart failure: an analysis from the dapagliflozin and prevention of adverse-outcomes in heart failure trial (DAPA-HF).
Sabatine MS, DeMets DL, Inzucchi SE, et al. Circulation. 2019;140(25):e973.
Diabetic kidney disease.
Thomas MC, Brownlee M, Susztak K, et al. Nat Rev Dis Primers. 2015;1:15018.
SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome.
van Bommel EJ, Muskiet MH, Tonneijck L, et al. Clin J Am Soc Nephrol. 2017;12(4):700-710.
Empagliflozin and progression of kidney disease in type 2 diabetes.
Wanner C, Inzucchi SE, Lachin JM, et al. N Engl J Med. 2016;375(4):323-334.
Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
Wiviott SD, Raz I, Bonaca MP, et al. N Engl J Med. 2019;380(4):347-357.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA, Wiviott SD, Raz I, et al. Lancet. 2019;393(10166):31-39.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128.
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Relevant Resources
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Individualizing Evidence-Based Care
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCP’s Role in Timely Recognition and Referral
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Looking Beyond Hemoglobin A1c
Improving Patient Outcomes Through Shared Clinical Decision Making
What You Need to Know
Mechanistic Insights and Evolving Treatment Options
Clinical Resource Center
Implications for PCSK9 Inhibitors in Clinical Practice
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Best Practices for Diagnosis and Management
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
